BioDelivery Sciences International, Inc. (BDSI) Director Mark A. Sirgo Sells 709,502 Shares

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Director Mark A. Sirgo sold 709,502 shares of the stock in a transaction that occurred on Friday, January 19th. The stock was sold at an average price of $2.73, for a total transaction of $1,936,940.46. Following the transaction, the director now owns 1,759,262 shares in the company, valued at approximately $4,802,785.26. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of BioDelivery Sciences International, Inc. (NASDAQ BDSI) traded up $0.12 during trading on Friday, hitting $2.70. 532,970 shares of the stock were exchanged, compared to its average volume of 599,860. BioDelivery Sciences International, Inc. has a 12 month low of $1.55 and a 12 month high of $3.60. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.07 and a current ratio of 1.28. The company has a market cap of $150.89, a P/E ratio of 30.00 and a beta of 0.74.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its quarterly earnings results on Thursday, November 9th. The specialty pharmaceutical company reported ($0.21) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.01. BioDelivery Sciences International had a net margin of 10.40% and a return on equity of 33.83%. The company had revenue of $11.25 million during the quarter, compared to the consensus estimate of $9.40 million. During the same quarter in the prior year, the firm posted ($0.30) EPS. The firm’s quarterly revenue was up 215.1% on a year-over-year basis. equities analysts predict that BioDelivery Sciences International, Inc. will post 0.16 earnings per share for the current year.

A number of research analysts have issued reports on the stock. HC Wainwright set a $5.00 target price on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research report on Friday, October 13th. Roth Capital set a $5.00 price target on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a report on Thursday, October 12th. Cantor Fitzgerald set a $5.00 price target on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a report on Thursday, October 12th. Finally, Piper Jaffray Companies set a $4.00 price target on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a report on Sunday, October 22nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $4.29.

Several institutional investors have recently modified their holdings of the company. Northern Trust Corp lifted its stake in BioDelivery Sciences International by 0.9% in the 2nd quarter. Northern Trust Corp now owns 140,450 shares of the specialty pharmaceutical company’s stock valued at $394,000 after purchasing an additional 1,203 shares during the last quarter. Advisor Group Inc. lifted its stake in BioDelivery Sciences International by 42.1% in the 2nd quarter. Advisor Group Inc. now owns 45,066 shares of the specialty pharmaceutical company’s stock valued at $126,000 after purchasing an additional 13,341 shares during the last quarter. Wells Fargo & Company MN lifted its stake in BioDelivery Sciences International by 138.2% in the 3rd quarter. Wells Fargo & Company MN now owns 35,506 shares of the specialty pharmaceutical company’s stock valued at $105,000 after purchasing an additional 20,599 shares during the last quarter. Krilogy Financial LLC lifted its stake in BioDelivery Sciences International by 28.8% in the 3rd quarter. Krilogy Financial LLC now owns 134,000 shares of the specialty pharmaceutical company’s stock valued at $395,000 after purchasing an additional 30,000 shares during the last quarter. Finally, JPMorgan Chase & Co. bought a new position in BioDelivery Sciences International in the 3rd quarter valued at approximately $116,000. 44.08% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/01/19/biodelivery-sciences-international-inc-bdsi-director-mark-a-sirgo-sells-709502-shares.html.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Insider Buying and Selling by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply